Evolus Inc. Company Profile
NASDAQ: EOLSHealthcareDrug Manufacturers - Specialty & GenericUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Evolus at a glance
Evolus Inc. (NASDAQ: EOLS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector headquartered in Newport Beach, CA. Evolus is led by Mr. David Moatazedi and employs about 353 people. The company's shares have traded publicly since 2018.
At a market capitalization of $511.2 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001570562, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Evolus do?
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Business description based on the company's public filings.
Company information
- Legal name
- Evolus Inc.
- Ticker
- NASDAQ: EOLS
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. David Moatazedi
- Employees
- 353
- Headquarters
- 520 Newport Center Drive, Newport Beach, CA, United States
- Phone
- 949 284 4555
- Website
- evolus.com
- IPO year
- 2018
- Market cap
- $511.23M
- SEC CIK
- 0001570562
Companies similar to Evolus
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TKNOAlpha Teknova Inc. | 8.44 | -3.10% | $453.13M | vs EOLS |
| AQSTAquestive Therapeutics Inc. | 4.76 | +3.03% | $597.44M | vs EOLS |
| CGCCanopy Growth Corporation | 0.8468 | -3.39% | $380.47M | vs EOLS |
| ACBAurora Cannabis Inc. | 4.43 | -0.67% | $280.46M | vs EOLS |
| CPIXCumberland Pharmaceuticals Inc. | 6.98 | +1.31% | $104.58M | vs EOLS |
| CTORCitius Oncology Inc. | 0.835 | -2.45% | $88.31M | vs EOLS |
| INCRIntercure Ltd. | 5.03 | -1.95% | $75.47M | vs EOLS |
| TLPHTalphera Inc. | 1.08 | +2.86% | $56.06M | vs EOLS |